CD147 (EMMPRIN) and matrix metalloproteinase-2 expression in uterine endometrioid adenocarcinoma
Authors:
- 1 January 2011
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 207 (1) , 30-36
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasionJournal of Clinical Pathology, 2010
- MMP‐2, TIMP‐1, E‐cadherin, and β‐catenin expression in endometrial serous carcinoma compared with low‐grade endometrial endometrioid carcinoma and proliferative endometriumActa Obstetricia et Gynecologica Scandinavica, 2008
- Microenvironmental regulation of cancer developmentCurrent Opinion in Genetics & Development, 2008
- CD147 immunoglobulin superfamily receptor function and role in pathologyExperimental and Molecular Pathology, 2007
- MMP-2 expression associates with CA 125 and clinical course in endometrial carcinomaGynecologic Oncology, 2007
- Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressionsInternational Journal of Gynecological Cancer, 2006
- Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progressionCancer and Metastasis Reviews, 2006
- Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation studyAnnals of Oncology, 2006
- Expression Pattern of Metalloproteinases and Tissue Inhibitors of Matrix-Metalloproteinases in Cycling Human Endometrium1Biology of Reproduction, 2003
- Expression of Metalloproteinases and Their Inhibitors in Blood Vesselsin Human Endometrium1Biology of Reproduction, 1999